Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Delft – page 70

1 232 clinical trials in Delft, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Delft at a glance
1 232
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 232 trials in Delft

Open in trial search

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neurodegenerative disorder

Not recruiting

Study of Latozinemab for Patients with Neurodegenerative Diseases Who Previously Participated in a Latozinemab Study

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Giant cell tumour of tendon sheath

Not recruiting

Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emactuzumab
  • Sponsor:Synox Therapeutics Limited

Thymoma malignant

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Pulmonary fibrosis

Not recruiting

Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Alopecia areata

Not recruiting

Study of amlitelimab injection compared to placebo for adults with severe alopecia areata (hair loss)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Idiopathic pulmonary fibrosis+1

Not recruiting

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Interstitial lung disease

Not recruiting

Study on Pirfenidone Inhalation Solution for Patients with Progressive Fibrosing Interstitial Lung Diseases, Including Idiopathic Pulmonary Fibrosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Study of tiratricol treatment in children with MCT8 deficiency (Monocarboxylate Transporter 8 deficiency) to improve motor development

Not recruiting
InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Tiratricol
  • Sponsor:Rare Thyroid Therapeutics International AB

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Prostate cancer metastatic

Not recruiting

Study on LAVA-1207 and Pembrolizumab for Patients with Advanced Prostate Cancer Resistant to Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:LAVA Therapeutics N.V.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Delft

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on cardiovascular disease management and prevention, including studies of novel treatments for atherosclerotic cardiovascular disease and innovative therapies targeting lipoprotein reduction.

  • Lipid Management Studies
  • Cardiovascular Risk Prevention
  • Major Adverse Cardiac Events

Research exploring both established and experimental treatments to reduce cardiovascular complications and improve patient outcomes.

02 Oncology Studies

Comprehensive research into various cancer types, with significant focus on prostate cancer, breast cancer, and blood cancers including chronic lymphocytic leukemia.

  • Advanced Imaging Techniques
  • Targeted Therapies
  • Treatment Combinations

Innovative approaches combining established treatments with novel therapeutic agents to enhance treatment effectiveness.

03 Women's Health

Studies addressing various aspects of women's health, including infertility treatments and management of uterine fibroids.

  • Reproductive Health
  • Gynecological Conditions
  • Quality of Life Studies

Research comparing different treatment modalities and their impact on patient outcomes and quality of life.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.